•  home page
  •  location & contact
  • Español
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
Apr 16

EntreChem’s mithralogs show increased potency and higher selectivity for treatment of sarcoma

  • 16 April, 2012
  • Research
  • The fusion protein EWS-FLI1 ins a constitutively activated transcription factor responsible for the oncogenic phenotype of Ewing sarcoma. Mithramycin was identified last year out of 50.000 compounds as a potent inhibitor of EWS-FLI1, according to researchers at the National Cancer Institute and Vanderbilt University (USA).
  • EC-8042, a mithramycin analog (mithralog) under development at EntreChem SL, has shown better potency and increased selectivity relative to Mithramycin for both cell viability and downstream target inhibition. EC-8042 is known to be 20x less toxic than Mithramycin in xenograft models.

The results of a collaborative research from EntreChem SL (Oviedo, Spain), the National Cancer Institute (NCI, Bethesda, MD, USA) and Vanderbilt University (Nashville, TN, USA) focused on searching for a new strategy for treating Ewing Sarcoma, have been presented in a poster during the American Association for Cancer Research (AACR) annual meeting held on March 31st- April 4th in Chicago.The research, directed by Patrick Grohar, Ph.D. M.D., from the Division of Hematology-Oncology in the Department of Pediatrics at the Vanderbilt School of Medicine, and with contributions, among others, from Lee J. Helman, MD (Scientific Director NCI), Dr. Min He (DTP program, NCI) and Dr. Malcolm A. Smith (Clinical Investigation Branch, NCI) eva

luates the relative effects of Mithralogs on ESFT viability using MTS, XTT and IncuCyte® real time cell confluence assays. The compounds were screened against a panel of pediatric cell lines within the Pediatric Preclinical Testing Program (PPTP) to evaluate selectivity. Western blot analysis and Luciferase assays were used to determine the effects on EWS-FLI1 downstream target expression.

Two Mithramycin analogs, among them EC-8042, exhibit better potency and improved selectivity relative to Mithramycin for both cell viability and downstream target inhibition. In particular, EC-8042 compared to Mithramycin more effectively inhibits Luciferase activity driven by NR0B1 promoter (3.2 nM vs. 0.3 nM) as opposed to a non-specific CMV promoter (16 nM vs. 23 nM). Furthermore, EC-8042 is known to have an order of magnitude higher maximum tolerated dose (MTD) relative to the MTD of Mithramycin in xenograft models.

The inhibitor EC-8042, is currently undergoing preclinical development by EntreChem SL (therefore not yet available for human assays). EC-8042 is a hybrid natural product obtained from genetically modified bacteria by combinatorial biosynthesis.

EntreChem SL is a spin off company created from research developed in the University of Oviedo, and its shareholders include, aside from the original co-founders, local industry companies such as Industrial Química del Nalón, Alvargonzález SA and Alimerka. Private financing is complemented by regional, national and european public programs like NEOTEC program (MICINN), Genome Spain Foundation, FICYT, IDEPA, SRP and the Seventh Framework Programme from the European Union.

More information:
www.abstractsonline.com/Plan/AdvancedSearch.aspx
Dr. Patrick Grohar: patrick.grohar@vanderbilt.edu, +34 914 962 517
Dr. Francisco Morís Varas: fmv@entrechem.com, +1 615 936 1762

and also:
Vanderbilt University: pediatrics.mc.vanderbilt.edu (Division of Hematology/Oncology)
EntreChem SL: www.entrechem.com

latest news

  • AI-Therapeutics acquires the preclinical drugs EC-8042 and EC-70124 from EntreChem SL
  • EC-8042 targets SWI/SNF complex vulnerabilities and induces epigenetic reprogramming and permanent cures in rhabdoid tumor
  • EntreChem participates in the ERA-Co-Biotech project «MISSION»

categories

  • Agreements
  • Financing
  • Projects
  • Publications
  • Research
  • Other

archive

EntreChem, S.L.

Vivero Ciencias de la Salud,
c/ Colegio Santo Domingo de Guzmán s/n,
33011 Oviedo, Spain

info@entrechem.com

pipeline  /  chart
· EC-8042
· EC-70124

scientific collaborators
collaborative projects

  • about us
  • technology
  • publications
  • news
Copyright © 2023 EntreChem, S.L. All rights reserved.
  • privacy policy
  • usage policy
  • cookies policy

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview
entrechem

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

You can consult our cookies policy for more information.